Abstract
Sjögren's syndrome (SS) is a common chronic autoimmune disease characterized by lymphocytic infiltration of exocrine glands. The affected cases commonly present with oral and ocular dryness, which is thought to be the result of inflammatory cell-mediated gland dysfunction. To identify important molecular pathways involved in SS, we used high-density microarrays to define global gene expression profiles in the peripheral blood. We first analyzed 21 SS cases and 23 controls, and identified a prominent pattern of overexpressed genes that are inducible by interferons (IFNs). These results were confirmed by evaluation of a second independent data set of 17 SS cases and 22 controls. Additional inflammatory and immune-related pathways with altered expression patterns in SS cases included B- and T-cell receptor, insulin-like growth factor-1, granulocyte macrophage-colony stimulating factor, peroxisome proliferator-activated receptor-α/retinoid X receptor-α and PI3/AKT signaling. Exploration of these data for relationships to clinical features of disease showed that expression levels for most interferon-inducible genes were positively correlated with titers of anti-Ro/SSA (P<0.001) and anti-La/SSB (P<0.001) autoantibodies. Diagnostic and therapeutic approaches targeting interferon-signaling pathway may prove most effective in the subset of SS cases that produce anti-Ro/SSA and anti-La/SSB autoantibodies. Our results strongly support innate and adaptive immune processes in the pathogenesis of SS, and provide numerous candidate disease markers for further study.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 digital issues and online access to articles
$119.00 per year
only $19.83 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lahita RG . Sjögren's Syndrome: Textbook of the Autoimmune Diseases. Lippincott Williams & Wilkins: Philadelphia, 2000: 569–572pp.
Rhodus NL . An update on the management for the dental patient with Sjögren's syndrome and xerostomia. Northwest Dent 1999; 78: 27–34.
Masaki Y, Sugai S . Lymphoproliferative disorders in Sjogren's syndrome. Autoimmun Rev 2004; 3: 175–182.
Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR et al. Increased risk of lymphoma in sicca syndrome. Ann intern med 1978; 89: 888–892.
Fox PC, Speight PM . Current concepts of autoimmune exocrinopathy: immunologic mechanisms in the salivary pathology of Sjogren's syndrome. Crit Rev Oral Biol Med 1996; 7: 144–158.
Delaleu N, Jonsson R, Koller MM . Sjogren's syndrome. Eur J Oral Sci 2005; 113: 101–113.
Fox RI . Sjogren's syndrome. Lancet 2005; 366: 321–331.
Ogawa N, Dang H, Talal N . Apoptosis and autoimmunity. J Autoimmun 1995; 8: 1–19.
James JA, Harley JB, Scofield RH . Role of viruses in systemic lupus erythematosus and Sjogren syndrome. Curr Opin Rheumatol 2001; 13: 370–376.
Triantafyllopoulou A, Tapinos N, Moutsopoulos HM . Evidence for coxsackievirus infection in primary Sjogren's syndrome. Arthritis Rheum 2004; 50: 2897–2902.
Bolstad A, Jonsson R . Genetic aspects of Sjogren's syndrome. Arthritis Res 2002; 4: 353–359.
Miceli-Richard C, Comets E, Loiseau P, Puechal X, Hachulla E, Mariette X . Association of an IRF5 gene functional polymorphism with Sjogren's syndrome. Arthritis Rheum 2007; 56: 3989–3994.
Imanishi T, Morinobu A, Hayashi N, Kanagawa S, Koshiba M, Kondo S et al. A novel polymorphism of the SSA1 gene is associated with anti-SS-A/Ro52 autoantibody in Japanese patients with primary Sjogren's syndrome. Clin Exp Rheumatol 2005; 23: 521–524.
Pertovaara M, Hurme M, Antonen J, Pasternack A, Pandey JP . Immunoglobulin KM and GM gene polymorphisms modify the clinical presentation of primary Sjogren's syndrome. J Rheumatol 2004; 31: 2175–2180.
Pertovaara M, Lehtimaki T, Rontu R, Antonen J, Pasternack A, Hurme M . Presence of apolipoprotein E epsilon4 allele predisposes to early onset of primary Sjogren's syndrome. Rheumatology (Oxford) 2004; 43: 1484–1487.
Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI . Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis rheum 2005; 52: 1534–1544.
Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci USA 2006; 103: 2770–2775.
Baechler EC, Batliwalla FM, Reed AM, Peterson EJ, Gaffney PM, Moser KL et al. Gene expression profiling in human autoimmunity. Immunol Rev 2006; 210: 120–137.
Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554–558.
Hu S, Wang J, Meijer J, Ieong S, Xie Y, Yu T et al. Salivary proteomic and genomic biomarkers for primary Sjogren's syndrome. Arthritis Rheum 2007; 56: 3588–3600.
Wakamatsu E, Nakamura Y, Matsumoto I, Goto D, Ito S, Tsutsumi A et al. DNA microarray analysis of labial salivary glands of patients with Sjogren's syndrome. Ann Rheum Dis 2007; 66: 844–845.
Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100: 2610–2615.
Harada H, Takahashi E, Itoh S, Harada K, Hori TA, Taniguchi T . Structure and regulation of the human interferon regulatory factor 1 (IRF-1) and IRF-2 genes: implications for a gene network in the interferon system. Mol Cell Biol 1994; 14: 1500–1509.
Taniguchi T, Ogasawara K, Takaoka A, Tanaka N . IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 2001; 19: 623–655.
Zhang L, Pagano JS . Structure and function of IRF-7. J Interferon Cytokine Res 2002; 22: 95–101.
Ning S, Huye LE, Pagano JS . Regulation of the transcriptional activity of the IRF7 promoter by a pathway independent of interferon signaling. J Biol Chem 2005; 280: 12262–12270.
Harley JB, Alarcon-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008; 40: 204–210.
Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl j Med 2007; 357: 977–986.
Graham RR, Kyogoku C, Sigurdsson S, Vlasova IA, Davies LR, Baechler EC et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci USA 2007; 104: 6758–6763.
Korman BD, Alba MI, Le JM, Alevizos I, Smith JA, Nikolov NP et al. Variant form of STAT4 is associated with primary Sjogren's syndrome. Genes immun 2008; 9: 267–270.
Nordmark G, Alm GV, Ronnblom L . Mechanisms of disease: primary Sjogren's syndrome and the type I interferon system. Nat Clin Pract Rheumatol 2006; 2: 262–269.
Samuel CE . Antiviral actions of interferons. Clin Microbiol Rev 2001; 14: 778–809, table of contents.
Irie-Sasaki J, Sasaki T, Matsumoto W, Opavsky A, Cheng M, Welstead G et al. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature 2001; 409: 349–354.
Jacobsen M, Schweer D, Ziegler A, Gaber R, Schock S, Schwinzer R et al. A point mutation in PTPRC is associated with the development of multiple sclerosis. Nat Genet 2000; 26: 495–499.
Katz J, Stavropoulos F, Cohen D, Robledo J, Stewart C, Heft M . IGF-1 and insulin receptor expression in the minor salivary gland tissues of Sjogren's syndrome and mucoceles—immunohistochemical study. Oral Dis 2003; 9: 7–13.
Mustafa W, Mustafa A, Elbakri N, Link H, Adem A . Reduced levels of insulin-like growth factor-1 receptor (IGF-1R) suppress cellular signaling in experimental autoimmune sialadenitis (EAS). J Recept Signal Transduct Res 2001; 21: 47–54.
Tan NS, Michalik L, Desvergne B, Wahli W . Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes. J Steroid Biochem Mol Biol 2005; 93: 99–105.
Daynes RA, Jones DC . Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002; 2: 748–759.
Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999; 274: 32048–32054.
Dunn SE, Ousman SS, Sobel RA, Zuniga L, Baranzini SE, Youssef S et al. Peroxisome proliferator-activated receptor (PPAR)alpha expression in T cells mediates gender differences in development of T cell-mediated autoimmunity. J Exp Med 2007; 204: 321–330.
Sertznig P, Seifert M, Tilgen W, Reichrath J . Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases. Am J Clin Dermatol 2008; 9: 15–31.
Beauregard C, Brandt PC . Peroxisome proliferator-activated receptor agonists inhibit interleukin-1beta-mediated nitric oxide production in cultured lacrimal gland acinar cells. J Ocul Pharmacol Ther 2003; 19: 579–587.
Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Moser K, Ortmann WA et al. Expression levels for many genes in human peripheral blood cells are highly sensitive to ex vivo incubation. Genes immun 2004; 5: 347–353.
Eisen MB, Spellman PT, Brown PO, Botstein D . Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 14863–14868.
Whitney AR, Diehn M, Popper SJ, Alizadeh AA, Boldrick JC, Relman DA et al. Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci USA 2003; 100: 1896–1901.
Acknowledgements
This study was funded by NIH NIAMS RO1 AR050782 and the Phileona Foundation (KLM). The authors are grateful for resources provided by the University of Minnesota Supercomputing Institute and the Affymetrix core. We also thank Carolyn M Meyer, Amber N Leiran, Liliana Tobon, Daniella Machado and Julie Ermer for their technical assistance, and Jennifer Lessard for assistance with graphics. Finally, we thank the study participants without whom this study would not be possible.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on Genes and Immunity website (http://www.nature.com/gene)
Supplementary information
Rights and permissions
About this article
Cite this article
Emamian, E., Leon, J., Lessard, C. et al. Peripheral blood gene expression profiling in Sjögren's syndrome. Genes Immun 10, 285–296 (2009). https://doi.org/10.1038/gene.2009.20
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gene.2009.20
Keywords
This article is cited by
-
Mucosal immunology of the ocular surface
Mucosal Immunology (2022)
-
The promise of precision medicine in rheumatology
Nature Medicine (2022)
-
Sjögren’s syndrome: a systemic autoimmune disease
Clinical and Experimental Medicine (2022)
-
Genome-wide association study identifies Sjögren’s risk loci with functional implications in immune and glandular cells
Nature Communications (2022)
-
Investigation of type I interferon responses in ANCA-associated vasculitis
Scientific Reports (2021)